• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRI™ Website
      • ISPRI Downselect™
      • ISPRI Quantify™
      • ISPRI Analyze™
      • ISPRI Evaluate™
      • ISPRI-HCP™
      • ISPRI Design™
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAX™
      • EpiCC™
      • The Personalized Cancer Vaccine Platform
      • PreVAX™
    • Lab Services
      • All In Vitro Assays
      • Generic Peptide PANDA® Assays
    • Consulting Services
      • Trusted Expert Advice (TEA)
      • IRA / ISI Regulatory Writing Support
    • Why Immunogenicity Risk Assessment?
    • Why EpiVax?
  • About Us
    • Company History
    • Leadership
    • Careers
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
Most Recent Publications
Poster: Immunogenicity Risk Assessment of Salmon Calcitonin Peptide Impurities Using In Silico and In Vitro Methods

05-2024

Poster: Rapid and Predictive Immunogenicity Risk Assessments Using In Silico Methods

05-2024

Poster: Comprehensive assessment of immunogenicity risk of host cell proteins in biologics and vaccines using in silico and in vitro methods

05-2024

Poster: An “I” (Immunogenicity Risk Assessment) for an Eye (Ophthalmology Biologics)

05-2024

Individual and population-level variability in HLA-DR associated immunogenicity risk of biologics used for the treatment of rheumatoid arthritis

05-2024

In silico methods for immunogenicity risk assessment and human homology screening for therapeutic antibodies

04-2024

Neoadjuvant personalized cancer vaccines: the final frontier?

01-2024

Poster: T cell Epitope Content Comparison (EpiCC) of swine H1 influenza A virus hemagglutinin to identify best vaccine match

01-2024

A SARS-CoV-2 NSP7 homolog of a Treg epitope suppresses CD4+ and CD8+ T cell memory responses

11-2023

Development of IFNβ-1a versions with reduced immunogenicity and full in vitro biological activity for the treatment of multiple sclerosis

11-2023

Poster: In silico immunogenicity risk assessment for fusion proteins and novel antibody modalities

11-2023

Does human homology reduce the potential immunogenicity of non-antibody scaffolds?

10-2023

« Older Entries
Next Entries »

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

News

Events

Publications

Contact Us

Manage Consent

This website uses cookies and similar technologies to collect information about your website experience for advertising, analytics, and other purposes as described in our Privacy Policy. 

Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}